{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:08:54Z","timestamp":1789434534514,"version":"build-2803163510"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"38","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"the General Program of Middle-aged and Young Research Fund of Affiliated Hospital of Qinghai University","award":["ASRF-2022-YB-04"],"award-info":[{"award-number":["ASRF-2022-YB-04"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,19]]},"abstract":"<jats:p>This study investigates the clinical prognostic value of CD24 antigen expression level in patients with newly diagnosed multiple myeloma. A retrospective cohort study design was used to quantify the intensity of CD24 membrane surface expression in bone marrow specimens of 54 patients with primary diagnosis of multiple myeloma (MM) by flow cytometry, and the cohort was divided into a high-expression group (n\u2005=\u200524) and a low-expression group (n\u2005=\u200530) using the median expression value (5.05%) as the threshold. Baseline clinical characteristics of patients in the 2 groups were systematically collected, including age, Durie\u2013Salmon stage, ISS stage, \u03b22-microglobulin, serum lactate dehydrogenase, and other parameters, and the survival curves were plotted using the Kaplan\u2013Meier method and compared with the differences in overall survival by the log-rank test. The Cox proportional risk regression model was further applied to adjust for potential confounders. The median overall survival in the CD24 high-expression group was significantly better than in the low-expression group (50 months vs 24 months, hazard ratio\u2005=\u20050.41, 95% confidence interval\u2005=\u20050.21\u20130.97, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.04). Multifactorial analysis showed that high CD24 expression could be used as an independent prognostic factor, and its prognostic value was independent of ISS staging and cytogenetic risk stratification. Differential expression of CD24 in patients with a primary diagnosis of MM has a significant prognostic stratification value, and the high-expression profile suggests a superior survival expectancy, this biomarker may influence the disease process by modulating plasma cell adhesion-mediated drug resistance mechanisms, providing a new laboratory basis for precise prognostic assessment in MM.<\/jats:p>","DOI":"10.1097\/md.0000000000044298","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:02:19Z","timestamp":1758574939000},"page":"e44298","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["CD24 expression for better outcome prediction in newly diagnosed multiple myeloma patients"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4646-8246","authenticated-orcid":false,"given":"Lu","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Qinghai University, Xining, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1290-5551","authenticated-orcid":false,"given":"Hui","family":"Geng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Qinghai University, Xining, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Qinghai University, Xining, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youliang","family":"Li","sequence":"additional","affiliation":[{"name":"Orthopedic Joint Department, Affiliated Hospital of Qinghai University, Xining, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qichao","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Qinghai University, Xining, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9633-8900","authenticated-orcid":false,"given":"Yan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Xuan Wu Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250928","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management.","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"R2-20250928","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1200\/JCO.23.01277","article-title":"Genomic classification and individualized prognosis in multiple myeloma.","volume":"42","author":"Maura","year":"2024","journal-title":"J Clin Oncol"},{"key":"R3-20250928","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma.","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"R4-20250928","doi-asserted-by":"crossref","first-page":"e433520","DOI":"10.1200\/EDBK_433520","article-title":"Navigating high-risk and ultrahigh-risk multiple myeloma: challenges and emerging strategies.","volume":"44","author":"Rees","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R5-20250928","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","article-title":"Multiple myeloma with high-risk cytogenetics and its treatment approach.","volume":"115","author":"Hanamura","year":"2022","journal-title":"Int J Hematol"},{"key":"R6-20250928","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/ajh.27327","article-title":"High-risk multiple myeloma: redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapy.","volume":"99","author":"Rees","year":"2024","journal-title":"Am J Hematol"},{"key":"R7-20250928","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a european myeloma network (EMN) report within the HARMONY project.","volume":"40","author":"D\u2019Agostino","year":"2022","journal-title":"J Clin Oncol"},{"key":"R8-20250928","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41467-024-44873-4","article-title":"Bispecific BCMA\/CD24 CAR-T cells control multiple myeloma growth.","volume":"15","author":"Sun","year":"2024","journal-title":"Nat Commun"},{"key":"R9-20250928","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.18632\/oncotarget.27190","article-title":"The role of CD24 in multiple myeloma tumorigenicity and effects of the microenvironment on its expression.","volume":"10","author":"Gilad","year":"2019","journal-title":"Oncotarget"},{"key":"R11-20250928","doi-asserted-by":"crossref","first-page":"98931","DOI":"10.18632\/oncotarget.22131","article-title":"CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma.","volume":"8","author":"Alaterre","year":"2017","journal-title":"Oncotarget"},{"key":"R12-20250928","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/jnci\/djz159","article-title":"Identification and characterization of tumor-initiating cells in multiple myeloma.","volume":"112","author":"Gao","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"R13-20250928","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group.","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"R15-20250928","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.2147\/OTT.S366625","article-title":"CD24 as a potential therapeutic target in patients with B-cell leukemia and lymphoma: current insights.","volume":"15","author":"Christian","year":"2022","journal-title":"OncoTargets Therapy"},{"key":"R16-20250928","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13036-018-0129-0","article-title":"CD24 identifies nucleus pulposus progenitors\/notochordal cells for disc regeneration.","volume":"12","author":"Liu","year":"2018","journal-title":"J Biol Eng"},{"key":"R17-20250928","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","article-title":"CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.","volume":"572","author":"Barkal","year":"2019","journal-title":"Nature"},{"key":"R18-20250928","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1038\/s41388-024-03156-4","article-title":"ALDH1A3 is the switch that determines the balance of ALDH+ and CD24\u2010CD44+ cancer stem cells, EMT-MET, and glucose metabolism in breast cancer.","volume":"43","author":"Fernando","year":"2024","journal-title":"Oncogene"},{"key":"R19-20250928","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2174\/1566523220666200623170738","article-title":"CD24, a review of its role in tumor diagnosis, progression and therapy.","volume":"20","author":"Ni","year":"2020","journal-title":"Curr Gene Ther"},{"key":"R20-20250928","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41416-024-02743-2","article-title":"Associations of stem cell markers CD44, CD24 and ALDH1A1 with mammographic breast density in women with benign breast biopsies.","volume":"131","author":"Yaghjyan","year":"2024","journal-title":"Br J Cancer"},{"key":"R21-20250928","doi-asserted-by":"crossref","first-page":"1367959","DOI":"10.3389\/fimmu.2024.1367959","article-title":"Checkpoint CD24 function on tumor and immunotherapy.","volume":"15","author":"Huang","year":"2024","journal-title":"Front Immunol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044298","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:02:44Z","timestamp":1759046564000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":19,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044298","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"2025-05-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}